Abbott Laboratories
Decision brief
Abbott (ABT) closed at $104.49 on July 27, 2026, up 12.9% over the past month following the Q2 2026 earnings beat and raised full-year guidance. The at 18.67 indicates a neutral market regime, while the 10-year yield at 4.64% continues to pressure defensive multiples, though ABT's low forward of 17.2x provides a margin of safety. The fundamental thesis strengthened with Q2 adjusted of $1.31 beating by 2.3%, revenue up 13% YoY to $12.59B, and full-year guidance raised to $5.45-$5.60. Growth is driven by Medical Devices (+8.4% comparable) and Cancer Diagnostics (+13.3% comparable), while Nutrition trends are improving sequentially. The balance sheet remains solid with $7.3B cash and $34.1B debt. Technically, the stock is above ($95.94) and ($94.18) with a bullish and expanding histogram, but at 70.2 is overbought, suggesting potential for short-term consolidation. Post-earnings, multiple analysts raised price targets, with the mean target of $119.13 implying 14% upside. Estimate revisions for FY2026 have turned positive, though current quarter saw a slight trim. Insider activity remains strongly bullish with CEO purchases totaling $23M. The primary risk is NEC litigation, but a DOJ policy shift may reduce liability. Overall, the setup remains attractive for long-term investors, with near-term caution warranted due to overbought conditions.
Decision
$104.49
Recommendation score
86%Confidence
85%Outlook by horizon
1M
Near
6M
Mid
1Y
Long
Primary catalyst
Q2 earnings beat and raised guidance triggered a 10.7% single-day surge, reinforcing the operational turnaround narrative.
Price rail
$93.00
$100.00 - $102.00
$106.96 - $119.13
Risk / reward
1.5x
Downside to stop
-11.0%
Upside to exit
+14.0%
Position sizing
Full position sizing is appropriate given the neutral and strong post-earnings clarity. However, maintain a stop loss to protect against adverse litigation news or market selloff. Consider reducing to 75% if rises above 25 or litigation escalates.
Why It Works
What Breaks It
NEC litigation outcomes remain uncertain; worst-case liability could exceed $10B, impairing balance sheet and dividend. High interest rates may compress multiples further. Nutrition weakness may persist. The stock is still below , indicating long-term trend not yet bullish. Limited upside per some targets (~$108 per Zacks).
A daily close below $92.00 (below and major support) or a significant adverse NEC court ruling that increases estimated liability by >$5B, or a downward guidance revision on next earnings call.
Watch Next
Decision inputs
6 signalsFundamental
14.0%
Upside to analyst mean target
ABT trades at 17.2x forward , a significant discount to its 5-year median of approximately 23x and to the broader healthcare sector. The ratio of 2.08 is above the 1.5x threshold but justified by durable growth and strong FCF generation. of 17.4x is in line with historical averages. Given raised guidance, the stock appears undervalued relative to intrinsic value.
Technical
Bullish
Trend quality
Short-term trend is strongly bullish, with price ($104.49) above ($95.94) and ($94.18), both sloping upward. The has recently crossed above ? Actually, is above , indicating near-term momentum acceleration. Long-term trend remains bearish with price below ($106.96), but the gap is narrowing. Trend is transitioning from downtrend to potential uptrend.
Earnings
78d
Accelerating
Q2 2026 adjusted of $1.31 beat consensus by 2.3%, revenue exceeded by 0.9%, and full-year guidance was raised to $5.45-$5.60. The market reacted positively with a 10.7% surge on the release day.
News
Bullish
Headline tone
Q2 earnings beat and raised guidance triggered a 10.7% single-day surge, reinforcing the operational turnaround narrative.
Macro
Neutral
4.64% 10Y / 18.7 VIX
Elevated 10Y yield (4.64%) continues to pressure defensive valuations, but ABT's low forward (17.2x) and robust company-specific drivers (earnings beat, raised guidance, MedTech acceleration) partially insulate the stock from macro headwinds.
Stability
Defensive Compounder
Core Anchor
Abbott's diversified healthcare portfolio, essential product lines, and 54-year dividend growth streak make it a core defensive holding. While litigation and interest rate risks present medium-term drawdown potential, the business quality and cash flow stability support high thesis durability. The stock should serve as a foundation in a diversified portfolio.
Mean Target
$119.13
High / Low
$103 / $135
Median Target
$119.00
Consensus range
$103 - $135
Consensus
Mean target of $119.13 implies 14% upside from current price. Wide spread ($103 low to $135 high) reflects uncertainty around litigation and nutrition, but recent upward revisions suggest growing confidence. The low target has been essentially met, likely to be raised.
Insider Signal
Strong Buy
Net Bias
Buy-heavy
Insider Own.
0.5%
Institutional Own.
82.5%
Interpretation
Management's substantial personal investment signals strong confidence in the turnaround and undervaluation.
Notable activity
CEO Robert Ford executed two open-market purchases totaling approximately $23.2 million in late April/early May 2026, near the stock's low. No significant insider sales have been recorded. A small purchase by an officer also occurred.
Industry
Sentiment
63
Tracked names
1
Grouping
industry
Medical Devices industry is currently Bullish with an average recommendation score near 86. positioning is broadly steady, and leadership is still concentrated.
Rotation Drivers
Leaders To Watch
No other tracked leaders yet.
Themes
Score: 85
Abbott's pivot to higher-margin Medical Devices and Diagnostics is driving accelerating growth, confirmed by Q2 results. New product launches and expanding CGM reimbursement support sustained momentum. This theme is strengthening, though the elevated tempers near-term enthusiasm.
Q2 earnings beat and raised guidance confirm operational acceleration.
Market Cap
$182.00B
P/E (TTM)
33.8
Forward P/E
17.2
Revenue Growth
13.0%
ROE
0.0%
Beta
0.61
Full Metric Set
17 additional stats
Valuation Stack
Multiples and cash-flow framing.
Price / Sales
3.9
Price / Book
3.5
EV / EBITDA
17.4
Quality & Balance Sheet
Margins, leverage, and liquidity.
Gross Margin
56.8%
Operating Margin
14.2%
Debt / Equity
64.8
Current Ratio
0.00x
Quick Ratio
0.00x
Positioning & Range
Short interest and 52-week location.
Short % Float
1.6%
Short Ratio
1.83x
52W High
$137.49
52W Low
$81.97
From 52W High
-24.0%
From 52W Low
27.5%
Company Classification
Sector and industry context.
Sector
Healthcare
Industry
Medical Devices
Additional Signals
Free Cash Flow
$0.00
Business Quality
Capital Allocation
Estimate Revisions
Revenue Growth
13.0%
Insider Activity
EARNHARDT LISA D
Officer
22,852
$2.4M
FUNCK ROBERT E. JR.
Officer
10,097
$475k
FUNCK ROBERT E. JR.
Officer
10,097
$1.1M
MCCOY JOHN A. JR
Officer
27
$3k
News Catalysts
Jul 27, 2026
Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth?
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper […]
Jul 27, 2026
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth
Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Strategy”. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]
Jul 27, 2026
Is Abbott Stock Attractive After Its Earnings and Guidance Update?
ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?
Jul 27, 2026
Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson
GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results.